VENMAX.BO · BSE
VENMAX DRUGS AND PHARMACEUTICA
₹14.81
+8.90% (+₹1.21)
Prev. close
₹13.6
Volume
26,101
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About VENMAX DRUGS AND PHARMACEUTICA
Venmax Drugs and Pharmaceuticals Limited engages in the business of pharmaceutical products, drug intermediaries, and API's in India. The company was formerly known as Yenkey Drugs & Pharmaceuticals Ltd and changed its name to Venmax Drugs and Pharmaceuticals Limited in April 2009. Venmax Drugs and Pharmaceuticals Limited was incorporated in 1988 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. G. Pradeep Kumar
Headquarters
Hyderabad
Employees
2
Website
venmaxdrugs.comExchange
View on BSE ↗Key stats
Market cap
₹21.51 Cr
P/E ratio (TTM)
61.9
EPS (TTM)
₹0.24
Beta (1Y · daily vs NIFTY 50)
0.74
Beta (5Y · monthly vs NIFTY 50)
-0.50
Shares float
87.35 L
EPS · quarter ended Jun 2026
₹0.10
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
Other assets floored at zero for years where fixed and current assets exceeded reported total assets.
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹0 | ₹0 | ₹80.70 L | ₹8.03 Cr | |
| EBITDA | ₹23.38 L | ₹-10.47 L | ₹-68,000 | ₹28.10 L |
| ₹22.56 L | ₹6.45 L | ₹-1.40 L | ₹24.80 L | |
| Diluted EPS | ₹0.43 | ₹0.12 | ₹-0.02 | ₹0.21 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹21.14 L | ₹8.14 L | ₹5.17 Cr | ₹16.20 Cr | |
| ₹35.21 L | ₹35.21 L | ₹4.96 L | ₹33.09 L | |
| Stockholders' equity | ₹-71.45 L | ₹-65.01 L | ₹4.41 Cr | ₹14.12 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-31,000 | ₹22,000 | ₹-2.29 Cr | ₹-11.00 Cr | |
| Investing cash flow | — | ₹0 | ₹0 | ₹0 | ₹0 |
| — | ₹31,000 | ₹0 | ₹4.77 Cr | ₹9.74 Cr | |
| End cash position | — | ₹3,000 | ₹25,000 | ₹2.48 Cr | ₹1.22 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| VENMAX DRUGS AND PHARMACEUTICA | ₹19.70 Cr | ₹13.6 | 56.7 | 1.40 | 1.8% | 0.02 | +894.0% | -46.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.